New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Subscribe To Our Newsletter & Stay Updated
